Participación de células troncales tumorales en la progresión de neoplasias.
Identificación de blancos terapéuticos y desarrollo de nuevos agentes para el tratamiento del cáncer.
Diseño y descubrimiento de fármacos asistido por computadora.
Evaluación preclínica de fármacos biológicos y biotecnológicos.

Publicaciones

1. Cordova-Bahena L, Landero-Marín C, Flores-Hernández X, Jiménez-Uribe AP, Salinas-Jazmín N, An Z, Velasco-Velázquez MA*. In silico-driven identification of pranlukast as a PD-L1 homodimer stabilizer. Anticancer Agents Med. Chem. En prensa, 2024. [doi: 10.2174/0118715206303675241009104647]. FI: 2.8
2. Salinas-Jazmín N, Mondragón-Medina MA, Jiménez-López J, Guerrero-Rodríguez SL, Cuautle-Rodríguez P, Velasco-Velázquez MA. Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter. Cancer Chemother. Pharmacology. En prensa, 2024. [doi: 10.1007/s00280-024-04701-4]. FI: 2.7
3. Ruiz-Moreno AJ, Cedillo-González R, Cordova-Bahena L, An Z, Medina-Franco JL, Velasco-Velázquez MA*. A consensus pharmacophore strategy for identifying novel SARS-CoV-2 Mpro inhibitors from large chemical libraries. J. Chem. Inf. Model. 64: 1984−1995, 2024. [doi: 10.1021/acs.jcim.3c01439]. FI: 5.6
4. Juárez-Mercado KE, Gómez-Hernández MA, Salinas-Trujano J, Espitia C, Perez-Tapia SM. Medina-Franco JL*, Velasco-Velázquez MA*. Identification of SARS-CoV-2 main protease (Mpro) inhibitors by chemical similarity analysis combined with machine learning. Pharmaceuticals. 17: 240, 2024. [doi: 10.3390/ph17020240]. FI: 4.6
5. De La Cruz-Sigüenza DA, Reyes-Grajeda JP, Velasco-Velázquez MA, Trejo-Becerril C, Pérez-Cárdenas E, Chávez-Blanco AD, Taja-Chayeb L, Domínguez-Gómez G, Ramos-Godinez P, González-Fierro A, Dueñas-González A. The non-vesicle extracellular DNA induces cell transformation associated with horizontal DNA transfer. Mol. Biol. Rep. 51:174, 2024. [doi: 10.1007/s11033-023-09016-w]. FI: 2.800
6. Duarte-Campos J, Vázquez-Moreno N, Martínez-Marcial M, Chavarría A, Ramírez-Carreto RJ, Velasco-Velázquez MA, De La Fuente-Granada M, González-Arenas A. Changes in neuroinflammatory markers, microglial density and distribution in the hippocampus of the C58/J mouse model of autism. Eur. J. Neurosci. 59: 154-173, 2024 [doi: 10.1111/ejn.16204]. FI: 3.400
7. Zaa C, Marcelo AJ, An Z, Medina-Franco JL, Velasco-Velázquez MA*. Anthocyanins: molecular aspects of their neuroprotective activity. Biomolecules 13: 1598, 2023 [doi: 10.3390/biom13111598]. FI: 5.500
8. Zaa C, Espitia C, Reyes-Barrera KL, An Z, Velasco-Velázquez MA*. Neuroprotective agents with therapeutic potential for COVID-19. Biomolecules 13: 1585, 2023 [doi: 10.3390/biom13111585]. FI: 5.500
9. Hernandez-Peralta P, García-Espejo DA, Gracia-Mora MI, Velasco-Velázquez MA, Cobos-Marín L. Agave mapisaga aqueous extract shows in vitro and in vivo activity on murine prostate cancer cells. Bol. Latinoam. Caribe Plantas Med. Aromát. 22: 37-47, 2023 [doi: 10.37360/blacpma.23.22.1.3]. FI: 0.700
10. Guerrero-Rodríguez SL, Mata-Cruz C, Pérez-Tapia SM, Velasco-Velázquez MA*. Role of CD36 in cancer progression, stemness, and targeting. Front. Cell Dev. Biol. 10:1079076, 2022. [doi: 10.3389/fcell.2022.1079076]. FI: 6.081
11. Rosas-Cruz A, Salinas-Jazmín N, Valdés-Rives A, Velasco-Velázquez MA*. DRD1 and DRD4 are differentially expressed in breast tumors and breast cancer stem cells: pharmacological implications. Transl. Cancer Res. 11: 3941-3950, 2022 [doi: 10.21037/tcr-22-783]. FI: 1.241
12. Hernández-Rojas R, Jiménez-Arellano C, De la Fuente-Granada M, Ordaz-Rosado D, García-Becerra R, Valencia-Mayoral P, Álvarez-Arellano ML, Velasco-Velázquez M, González-Arenas A. The interplay between estrogen receptor beta and PKCs, a crucial collaboration for medulloblastoma cell proliferation and invasion. Cell. Signal. 13: 110246, 2022 [doi: 10.1016/j.cellsig.2022.110246]. FI: 4.315
13. Sadremomtaz A, Al-Dahmani ZM, Ruiz-Moreno, AJ, Monti A, Wang C, Azad T, Bell J, Doti N, Velasco-Velázquez MA, de Jong D, de Jonge J, Dömling A, van Goor H, Groves MR. Synthetic Peptides that antagonise the Angiotensin-Converting Enzyme-2 (ACE-2) interaction with SARS-CoV-2 receptor binding spike protein S. J. Med. Chem. 65: 2836-2847, 2022 [doi: 10.1021/acs.jmedchem.1c00477]. FI: 7.446
14. Sánchez-Ramírez D, Medrano-Guzmán R, Candanedo- González F, Jazmín De Anda-González J, García-Rios LE, Vadim Pérez-Koldenkova V, Gutiérrez-de la Barrera M, Rodríguez-Enríquez S, Velasco-Velázquez M, Cecilia Pacheco-Velázquez S, Piña-Sánchez P, Mayani H, Gómez-Delgado A, Martínez-Lara AK, Montesinos JJ. High expression of both desmoplastic stroma and epithelial to mesenchymal transition markers associate with shorter survival in pancreatic ductal adenocarcinoma. Eur. J. Histochem. 66: 3360, 2022 [doi: 10.4081/ejh.2022.3360]. FI: 3.188
15. Cordova-Bahena L, Sánchez-Álvarez AA, Ruiz-Moreno A, Velasco-Velázquez MA*. Repositioning of etravirine as a potential CK1ε inhibitor by virtual screening. Pharmaceuticals 15: 8, 2022 [doi: 10.3390/ph15010008]. FI: 5.863
16. Ruiz-Moreno AJ, Reyes Romero A, Dömling A, Velasco-Velázquez MA*. In silico design and selection of new tetrahydroisoquinoline-based CD44 antagonist candidates. Molecules 26: 1877, 2021 [doi: 10.3390/molecules26071877]. FI: 4.411
17. Oerlemans R, Ruiz-Moreno AJ, Cong Y, Kumar ND, Velasco-Velázquez MA, Neochoritis C, Smith J, Reggiori F, Groves M, Dömling A. Repurposing the HCV NS3-4A Protease Drug Boceprevir as COVID-19 Therapeutics. RSC Med. Chem. 12: 370, 2021 [doi: 10.1039/d0md00367k]. FI: 2.394
18. Arcos-Montoya D, Wegman-Ostrosky T, Mejía-Pérez S, de la Fuente-Granada M, Camacho-Arroyo I, García-Carrancá A, Velasco-Velázquez MA, Manjarrez-Marmolejo J, Gonzalez-Arenas A. Progesterone receptor phosphorylation together with PKCα expression as a prognostic factor for astrocytomas malignancy. Onco Targets Ther. 14: 3757-3768, 2021 [doi: 10.2147/OTT.S280314]. FI: 4.147
19. Salinas-Jazmín N, Rosas-Cruz A, Velasco-Velázquez MA*. Reporter gene systems for the identification and characterization of cancer stem cells. World J. Stem Cells. 13: 1-15, 2021 [doi: 10.4252/wjsc.v13.i7.861]. FI: 5.326
20. Rosas-Cruz A, Salinas-Jazmín N, Velasco-Velázquez MA*. Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets? Technol. Cancer Res. Treat. 20: 1-13, 2021 [doi: 10.1177/15330338211027913]. FI: 3.399
21. Mejía-Calvo I, López-Juárez LE, Vázquez-Leyva s, López-Morales C, Montoya-Escutia D, Merlos Rivera P, Herbert-Pucheta JE, Zepeda-Vallejo LG, Velasco-Velázquez M, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Quality attributes of partially hydrolyzed collagen in a liquid formulation used for skin care. J. Cosmet. Dermatol. 20: 150-158, 2021 [doi:10.1111/jocd.13439]. FI: 2.696
22. Reyes-Romero A, Ruiz-Moreno AJ, Groves MR, Velasco-Velázquez M, Dömling A. Benchmark of Generic Shapes for Macrocycles. J. Chem. Inf. Mod. 60: 6298-6313, 2020 [doi: 10.1021/acs.jcim.0c01038]. FI: 4.549
23. Cordova-Bahena L, Velasco-Velázquez MA*. Anti-PD1 and anti-PD-L1 antibodies as immunotherapy against cancer: a structural perspective. Rev. Invest. Clin. 73: 3-11, 2021 [doi:10.24875/RIC.20000341]. FI: 1.451
24. Li J, Di Lorenzo V, Patil P, Ruiz-Moreno AJ, Kurpiewska K, Kalinowska-Tłuścik J, Velasco-Velázquez MA, Dömling A. Scaffolding-induced property modulation of chemical space. ACS Comb. Sci. 22: 356–360, 2020 [doi:10.1021/acscombsci.0c00072]. FI. 3.381
25. Camacho-Sandoval R, Jiménez-Uribe A, Tenorio-Calvo A, López-Morales CA, Muñoz-García L, Montes-Luna A, García-Xolalpa HL, Velasco-Velázquez MA, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Taking advantage of a high-throughput flow cytometer for the implementation of ADCC assay for regulatory compliance. Biotechnol. Rep. 26: e00456, 2020 [doi:10.1016/j.btre.2020.e00456]
26. Melgarejo-Rubio G, Pérez Tapia SM, Medina-Rivero E, Velasco-Velázquez MA*. Anticuerpos monoclonales conjugados a fármacos citotóxicos para el tratamiento del cáncer. Gac. Med. Mex. 156: 1-9, 2020 [doi:10.24875/GMM.20000388]. FI: 0.581
27. Perdomo-Abúndez FC, Vallejo-Castillo L, Vázquez-Leyva S, López-Morales CA, Velasco-Velazquez M, Pavón L, Pérez-Tapia SM, Medina-Rivero E. Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. J Chromatogr B Analyt Technol Biomed Life Sci. 1139: 121885, 2020 [doi:10.1016/j.jchromb.2019.121885]. FI: 3.004
28. Velázquez-Quesada I, Ruiz-Moreno AJ, Casique-Aguirre D, Aguirre-Alvarado C, Cortés-Mendoza F, de la Fuente-Granada M, García-Pérez CA, Pérez-Tapia SM, González-Arenas A, Segura-Cabrera A, Velasco-Velázquez MA*. Pranlukast antagonizes CD49f and reduces stemness in triple negative breast cancer cells. Drug Des. Devel. Ther. 14: 1799-1811, 2020 [doi:10.2147/DDDT.S247730]. FI: 3.216

Circuito de Posgrado, Ciudad Universitaria
Alcaldía Coyoacán, C.P. 04510, México, CDMX

55 5623 7006
mdcbq@posgrado.unam.mx